Online Inquiry

Fmoc-PEG4-NHS ester

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Category	Small-molecule Group Protected PEG
Catalog NO.	BPG-2373
Product Name	Fmoc-PEG4-NHS ester
CAS	1314378-14-7
Molecular Formula	C30H36N2O10
Molecular Weight	584.61

Scheme Design
Custom Synthesis
cGMP Manufacturing
Quality Assurance

Product Information
Application
References
Documents
Reviews

Product Information

Description	Fmoc-PEG4-NHS ester is a PEG derivative containing an Fmoc-protected amine and an NHS ester. The hydrophilic PEG spacer increases solubility in aqueous media. The Fmoc group can be deprotected under basic conditions to obtain the free amine which can be used for further conjugations. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.
Synonyms	Fmoc-NH-PEG4-NHS ester; Fmoc-PEG4-C2-NHS ester; Fmoc-NH-PEG4-NHS; FmocNH-PEG4-CH2CH2COONHS; Fmoc-PEG4-CH2CH2-NHS ester; Fmoc-N-amido-PEG4-NHS ester; α-(fmoc-amino)-omega-(succinimidyl propionate) tetra(ethylene glycol); 2,5-Dioxopyrrolidin-1-yl 1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oate; 9H-Fluoren-9-ylmethyl {15-[(2,5-dioxo-1-pyrrolidinyl)oxy]-15-oxo-3,6,9,12-tetraoxapentadec-1-yl}carbamate; Carbamic acid, N-[15-[(2,5-dioxo-1-pyrrolidinyl)oxy]-15-oxo-3,6,9,12-tetraoxapentadec-1-yl]-, 9H-fluoren-9-ylmethyl ester
IUPAC Name	(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoate
Canonical SMILES	C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCOCCNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
InChI	InChI=1S/C30H36N2O10/c33-27-9-10-28(34)32(27)42-29(35)11-13-37-15-17-39-19-20-40-18-16-38-14-12-31-30(36)41-21-26-24-7-3-1-5-22(24)23-6-2-4-8-25(23)26/h1-8,26H,9-21H2,(H,31,36)
InChIKey	NMCTTZZPHFQEQB-UHFFFAOYSA-N
Purity	≥95%
Density	1.3±0.1 g/cm3
Solubility	Soluble in DCM, DMF, DMSO
Appearance	Pale Yellow or Colorless Oily Liquid
Storage	Store at 2-8°C

Fmoc-PEG4-NHS ester, a versatile chemical reagent with diverse applications in bioconjugate synthesis and peptide modifications, is explored through four intricate and richly varied applications displayed with a high degree of perplexity and burstiness:

Peptide Synthesis: Positioned as a pivotal player in peptide synthesis, Fmoc-PEG4-NHS ester shines for its ability to incorporate polyethylene glycol (PEG) spacers. This strategic enhancement not only boosts peptide solubility and stability, but also diminishes immunogenicity, making peptides more conducive for therapeutic use. The introduction of PEG spacers presents new avenues for peptide engineering, pushing the boundaries of biomedical exploration and innovation.

Protein Labeling: In the realm of protein modification, Fmoc-PEG4-NHS ester emerges as a crucial reagent for attaching PEG chains to proteins, optimizing their pharmacokinetic profiles. Through PEGylation, researchers can prolong the half-life of protein-based therapeutics in circulation, lessening protein aggregation and elevating therapeutic effectiveness. This custom modification approach holds immense potential for enhancing the potency of protein therapies and expanding their clinical applications, ushering in a new era of precision medicine.

Surface Functionalization: Unleashing the potential of surface science, Fmoc-PEG4-NHS ester acts as a cornerstone in functionalizing substrates like microarrays and biosensors with biomolecules. This tailored surface modification enables the creation of highly specific and sensitive diagnostic platforms, capable of capturing and detecting target analytes with exceptional accuracy. The integration of biomolecule-functionalized surfaces heralds a new era in biosensing technology, driving advancements in diagnostics and research with unparalleled precision and sophistication.

Drug Delivery Systems: Taking the lead in drug delivery innovation, Fmoc-PEG4-NHS ester plays a pivotal role in crafting advanced drug delivery systems that combine therapeutic agents with PEG molecules. This strategic union facilitates controlled drug release and targeted delivery, enhancing therapeutic efficacy while minimizing adverse effects. The integration of PEGylation in drug delivery strategies stands as a hallmark of precision medicine, offering novel pathways to improve patient outcomes and revolutionize treatment paradigms with precision and foresight.

Reviews

If you have any suggestions or comments about mPEG-Br, please submit a review immediately.